iNFixion Bioscience announces second NIH SBIR Phase 1 Grant award

iNFixion Bioscience announced today that it had been granted its second NIH Phase 1 SBIR Grant award from the National Institute of Neurological Disorders and Stroke (NINDS).  This 18-month grant, titled “Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency” is focused on identifying small molecule compounds that impact the rate of intracellular NF1 protein degradation.  This grant includes funding for an 18-month project that will be launched immediately, and includes continued collaboration with both the University of Wisconsin Biotechnology Center and Scripps Research in San Diego.